Editas Medicine, Inc.
Editas Medicine is a gene editing company developing genomic medicines for serious diseases. Its proprietary CRISPR platform includes Cas9, Cas12a and engineered variants, along with guide RNA design and delivery technologies. The company focuses its research and development on in vivo gene editing, including medicines targeting liver cells, hematopoietic stem cells and other tissues. Its lead development candidate, EDIT-401, is designed to reduce LDL cholesterol by increasing expression of the LDL receptor. Editas is also developing an in vivo approach for sickle cell disease and transfusion-dependent beta thalassemia, and collaborates with partners on engineered T-cell therapies. It earns money through licensing its gene editing technology and intellectual property, and through collaboration agreements that can provide payments and royalties. Editas Medicine is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $EDIT in the last 7 days.
No SEC Form 4 filings for $EDIT in the last 30 days.
See all $EDIT insider activity →Wells Fargo upgraded Editas Medicine (EDIT) to Overweight, raising its price target to $6 from $4. This follows the company's approval to start a Phase 1/2 trial for EDIT-401 in Australia, targeting a genetic condition. Editas has a P/S ratio of 6.15, below its historical median of 33.7x, and a GF Score of 51/100, indicating moderate fundamentals with weak profitability and financial strength.
Editas Medicine (EDIT) received approval to start a Phase 1/2 trial for EDIT-401, a gene-editing therapy for hyperlipidemia, in Australia. The company aims to begin dosing this year and report initial safety data in Q1 2027. New preclinical data showing durable LDL-C reduction will be presented at the AHA Scientific Sessions 2026.
Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.
Recent EDIT coverage spans financial news, technology and market movers.
The upgrade signals analyst confidence and may drive short‑term buying pressure.
Positive regulatory clearance may lift sentiment and drive short-term buying pressure.
Volatile intraday action reflecting mixed sentiment.
Buy rating may lift price.
Analyst upgrade and new price target provide fresh upside catalyst.
AlphAI scores every news story that mentions EDIT with an AI model for sentiment and relevance, and aggregates insider trades from Editas Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo upgraded Editas Medicine (EDIT) to Overweight, raising its price target to $6 from $4. This follows the company's approval to start a Phase 1/2 trial for EDIT-401 in Australia, targeting a genetic condition. Editas has a P/S ratio of 6.15, below its historical median of 33.7x, and a GF Score of 51/100, indicating moderate fundamentals with weak profitability and financial strength.
2 min readEditas Medicine (EDIT) received approval to start a Phase 1/2 trial for EDIT-401, a gene-editing therapy for hyperlipidemia, in Australia. The company aims to begin dosing this year and report initial safety data in Q1 2027. New preclinical data showing durable LDL-C reduction will be presented at the AHA Scientific Sessions 2026.
2 min readGene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.
2 min readStifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.
2 min readEditas Medicine (EDIT) stock rose 7.2% in pre-market trading after Guggenheim upgraded it to Buy with a $5.00 price target, citing strong preclinical data for EDIT-401, its gene therapy for severe hypercholesterolemia. The move is company-specific, with broader markets trading lower. EDIT's 52-week range is $1.66 to $4.54.
2 min readEditas Medicine (NASDAQ:EDIT) aims to dose patients with its LDL gene-editing therapy, EDIT-401, in 2026, targeting a human-equivalent dose of 0.6 mg/kg. The Phase I/II study has two parts, with initial safety data expected in Q1 2025 and top-line data in 2027. The company has $212M in cash, expected to last until mid-2028, supporting the study's advancement. Editas estimates a U.S. market of 9-10M patients for its therapy.
2 min readEditas Medicine (EDIT) is advancing EDIT-401, a CRISPR therapy aiming for up to 90% LDL cholesterol reduction. First patient dosing is expected this year, with safety data in Q1 2027 and top-line results in 2027. The company has a strong cash position to support these milestones, according to its Cantor Fitzgerald conference presentation.
1 min readEditas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.
2 min readEditas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei
4 min readEditas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. edit-20260617 0001650664 FALSE 0001650664 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________________ FORM 8-K _____________________________________________
2 min read
